Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 6/20 | 0.53 |
| ▸ | CASP3 | P42574 | 7/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CASP7 | P55210 | 4/20 | 0.37 |
| ▸ | CASP1 | P29466 | 3/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675161 | 1.00 | PSMB5 (0.53) | PSMB5CASP3PSMB8PSMB10PSMB2 | |
| SCHEMBL6673182 | 1.00 | PSMB5 (0.53) | PSMB5CASP3PSMB8PSMB10PSMB2 | |
| SCHEMBL8614260 | 0.93 | PSMB5 (0.46) | PSMB5CASP3CTSKCASP1FNTA | |
| SCHEMBL8614263 | 0.93 | PSMB5 (0.46) | PSMB5CASP3CTSKCASP1FNTA | |
| SCHEMBL6678268 | 0.88 | PSMB5 (0.43) | PSMB5CASP3CTSKFNTAFNTB | |
| SCHEMBL6672754 | 0.85 | PSMB5 (0.52) | PSMB5CASP3CTSKCASP7CASP1 | |
| SCHEMBL7113794 | 0.85 | PSMB5 (0.52) | PSMB5CASP3CTSKCASP7CASP1 | |
| SCHEMBL6672753 | 0.85 | PSMB5 (0.52) | PSMB5CASP3CTSKCASP7CASP1 | |
| SCHEMBL6678275 | 0.82 | PSMB5 (0.38) | PSMB5CTSKFNTAFNTBCTSS | |
| SCHEMBL13103136 | 0.81 | PSMB5 (0.48) | PSMB5CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0839155-B1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | MEDIVIR UK LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| EP-0839155-B1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | MEDIVIR UK LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-20030092067-A1 | Substrates and inhibitors of proteolytic enzymes | PEPTIDE THERAPEUTICS LIMITED | 2003-05-15 | — | — | US | disclosed |
| US-6528275-B1 | Screening for cleavage using combinatorial fluorescence resonance energy transfer (FRET) compounds of given formula; can use to accelerate drug discovery process | PEPTIDE THERAPEUTICS LIMITED (GB) | 2003-03-04 | — | — | US | disclosed |
| EP-0906333-B1 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | MEDIVIR UK LTD (GB) | 2001-07-25 | — | — | EP | disclosed |
| US-6034066-A | ANTIALLERGENS | PEPTIDE THERAPEUTICS LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |